Found: 61
Select item for more details and to access through your institution.
Maintenance Therapies in Indolent Lymphomas: should Recent Data Change the Standard of Care?
- Published in:
- 2017
- By:
- Publication type:
- journal article
MALT Lymphomas.
- Published in:
- 2003
- By:
- Publication type:
- journal article
Safety, tolerability, and preliminary activity of IMGN529, a CD37-targeted antibody-drug conjugate, in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: a dose-escalation, phase I study.
- Published in:
- Investigational New Drugs, 2018, v. 36, n. 5, p. 869, doi. 10.1007/s10637-018-0570-4
- By:
- Publication type:
- Article
Association of health-related quality of life with gender in patients with B-cell chronic lymphocytic leukemia.
- Published in:
- Supportive Care in Cancer, 2013, v. 21, n. 10, p. 2853, doi. 10.1007/s00520-013-1854-z
- By:
- Publication type:
- Article
Safety and efficacy of polatuzumab vedotin + obinutuzumab for relapsed/refractory non‐Hodgkin lymphomas: A phase IB/II study.
- Published in:
- American Journal of Hematology, 2022, v. 97, n. 1, p. E24, doi. 10.1002/ajh.26400
- By:
- Publication type:
- Article
A phase I/II study of the combination of panobinostat and carfilzomib in patients with relapsed or relapsed/refractory multiple myeloma: Final analysis of second dose‐expansion cohort.
- Published in:
- American Journal of Hematology, 2021, v. 96, n. 4, p. 428, doi. 10.1002/ajh.26088
- By:
- Publication type:
- Article
Combination trial of duvelisib (IPI‐145) with rituximab or bendamustine/rituximab in patients with non‐Hodgkin lymphoma or chronic lymphocytic leukemia.
- Published in:
- American Journal of Hematology, 2019, v. 94, n. 12, p. 1325, doi. 10.1002/ajh.25634
- By:
- Publication type:
- Article
Efficacy and safety of the dual SYK/JAK inhibitor cerdulatinib in patients with relapsed or refractory B‐cell malignancies: Results of a phase I study.
- Published in:
- American Journal of Hematology, 2019, v. 94, n. 4, p. E90, doi. 10.1002/ajh.25387
- By:
- Publication type:
- Article
Single‐agent ibrutinib versus chemoimmunotherapy regimens for treatment‐naïve patients with chronic lymphocytic leukemia: A cross‐trial comparison of phase 3 studies.
- Published in:
- American Journal of Hematology, 2018, v. 93, n. 11, p. 1402, doi. 10.1002/ajh.25259
- By:
- Publication type:
- Article
Duvelisib, an oral dual PI3K‐δ,γ inhibitor, shows clinical and pharmacodynamic activity in chronic lymphocytic leukemia and small lymphocytic lymphoma in a phase 1 study.
- Published in:
- American Journal of Hematology, 2018, v. 93, n. 11, p. 1318, doi. 10.1002/ajh.25243
- By:
- Publication type:
- Article
Duvelisib, an oral dual PI3K‐δ, γ inhibitor, shows clinical activity in indolent non‐Hodgkin lymphoma in a phase 1 study.
- Published in:
- American Journal of Hematology, 2018, v. 93, n. 11, p. 1311, doi. 10.1002/ajh.25228
- By:
- Publication type:
- Article
A phase II study of two dose levels of ofatumumab induction followed by maintenance therapy in symptomatic, previously untreated chronic lymphocytic leukemia.
- Published in:
- American Journal of Hematology, 2016, v. 91, n. 10, p. 1020, doi. 10.1002/ajh.24468
- By:
- Publication type:
- Article
A phase 2, multicenter study investigating ofatumumab and bendamustine combination in patients with untreated or relapsed CLL.
- Published in:
- American Journal of Hematology, 2016, v. 91, n. 9, p. 900, doi. 10.1002/ajh.24430
- By:
- Publication type:
- Article
Prognostic factors and jaw and renal complications among multiple myeloma patients treated with zoledronic acid.
- Published in:
- American Journal of Hematology, 2011, v. 86, n. 1, p. 25, doi. 10.1002/ajh.21912
- By:
- Publication type:
- Article
Comparison of organ residence time estimation methods for radioimmunotherapy dosimetry and treatment planning—patient studies.
- Published in:
- Medical Physics, 2009, v. 36, n. 5, p. 1595, doi. 10.1118/1.3100265
- By:
- Publication type:
- Article
ABCL-040: Pirtobrutinib (LOXO-305), a Next-Generation, Highly Selective, Non-Covalent Bruton's Tyrosine Kinase Inhibitor in Previously Treated Mantle Cell Lymphoma and Other Non-Hodgkin Lymphomas: Phase 1/2 BRUIN Study Results.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S378, doi. 10.1016/S2152-2650(21)01863-2
- By:
- Publication type:
- Article
CLL-139: Acalabrutinib ± Obinutuzumab vs Obinutuzumab + Chlorambucil in Treatment-Naïve Chronic Lymphocytic Leukemia: ELEVATE-TN 4-Year Follow-up.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S318, doi. 10.1016/S2152-2650(21)01751-1
- By:
- Publication type:
- Article
Poster: ABCL-040: Pirtobrutinib (LOXO-305), a Next-Generation, Highly Selective, Non-Covalent Bruton's Tyrosine Kinase Inhibitor in Previously Treated Mantle Cell Lymphoma and Other Non-Hodgkin Lymphomas: Phase 1/2 BRUIN Study Results.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S241, doi. 10.1016/S2152-2650(21)01513-5
- By:
- Publication type:
- Article
Poster: CLL-139: Acalabrutinib ± Obinutuzumab vs Obinutuzumab + Chlorambucil in Treatment-Naïve Chronic Lymphocytic Leukemia: ELEVATE-TN 4-Year Follow-up.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S220, doi. 10.1016/S2152-2650(21)01390-2
- By:
- Publication type:
- Article
Safety and Efficacy of Acalabrutinib Plus Bendamustine and Rituximab (BR) in Patients with Treatment-Naive (TN) or Relapsed/Refractory (R/R) Mantle Cell Lymphoma (MCL).
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2019, v. 19, p. S317, doi. 10.1016/j.clml.2019.07.293
- By:
- Publication type:
- Article
An Improved Benefit-Risk Profile of Duvelisib in Patients with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Who Received ≥2 Prior Therapies.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2019, v. 19, p. S276, doi. 10.1016/j.clml.2019.07.209
- By:
- Publication type:
- Article
Patterns of Duvelisib-Induced Lymphocytosis in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Including Those with High-Risk Factors Treated in the DUO Trial.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2019, v. 19, p. S275, doi. 10.1016/j.clml.2019.07.208
- By:
- Publication type:
- Article
Effect of Dose Modifications on Response to Duvelisib in Patients with Relapsed/Refractory (R/R) CLL/SLL in the DUO Trial.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2019, v. 19, p. S273, doi. 10.1016/j.clml.2019.07.204
- By:
- Publication type:
- Article
BELINDA: A Phase 3 Study Evaluating the Safety and Efficacy of Tisagenlecleucel versus Standard of Care in Adult Patients with Relapsed/Refractory Aggressive B-Cell Non-Hodgkin Lymphoma.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2019, v. 19, p. S270, doi. 10.1016/j.clml.2019.07.197
- By:
- Publication type:
- Article
Managing Cytokine Release Syndrome and Neurotoxicity with Step-Up Dosing of Mosunetuzumab in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2019, v. 19, p. S247, doi. 10.1016/j.clml.2019.07.151
- By:
- Publication type:
- Article
Tumor Debulking and Reduction in Risk of Tumor Lysis Syndrome with Single-Agent Ibrutinib.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2017, v. 17, p. S304, doi. 10.1016/j.clml.2017.07.100
- By:
- Publication type:
- Article
Differences in Quality of Life Between Bendamustine-Rituximab and R-CHOP/R-CVP in Patients With Previously Untreated Advanced Indolent Non-Hodgkin Lymphoma or Mantle Cell Lymphoma.
- Published in:
- 2016
- By:
- Publication type:
- journal article
Rituximab with or without bevacizumab for the treatment of patients with relapsed follicular lymphoma.
- Published in:
- 2014
- By:
- Publication type:
- Journal Article
B-Cell Receptor Pathobiology and Targeting in NHL.
- Published in:
- Current Oncology Reports, 2012, v. 14, n. 5, p. 411, doi. 10.1007/s11912-012-0254-8
- By:
- Publication type:
- Article
Autologous bone marrow transplantation with 4-hydroperoxycyclophosphamide purging for acute myeloid leukaemia beyond first remission: a 10-year experience.
- Published in:
- British Journal of Haematology, 2002, v. 117, n. 4, p. 907, doi. 10.1046/j.1365-2141.2002.03530.x
- By:
- Publication type:
- Article
Phase Ib study of avadomide (CC‐122) in combination with rituximab in patients with relapsed/refractory diffuse large B‐cell lymphoma and follicular lymphoma.
- Published in:
- EJHaem, 2022, v. 3, n. 2, p. 394, doi. 10.1002/jha2.394
- By:
- Publication type:
- Article
Phase Ib study of combinations of avadomide (CC‐122), CC‐223, CC‐292, and rituximab in patients with relapsed/refractory diffuse large B‐cell lymphoma.
- Published in:
- EJHaem, 2022, v. 3, n. 1, p. 139, doi. 10.1002/jha2.375
- By:
- Publication type:
- Article
Phase II Study of Bendamustine and Ofatumumab in Elderly Patients with Newly Diagnosed Diffuse Large B‐Cell Lymphoma Who Are Poor Candidates for R‐CHOP Chemotherapy.
- Published in:
- Oncologist, 2019, v. 24, n. 8, p. 1035, doi. 10.1634/theoncologist.2019-0286
- By:
- Publication type:
- Article
A Phase II Trial Evaluating the Safety of Rapid Infusion of Ofatumumab in Patients with Previously Treated Chronic Lymphocytic Leukemia.
- Published in:
- Oncologist, 2017, v. 22, n. 10, p. 1156, doi. 10.1634/theoncologist.2017-0236
- By:
- Publication type:
- Article
GS-1101: A Delta-Specific PI3K Inhibitor in Chronic Lymphocytic Leukemia.
- Published in:
- Current Hematologic Malignancy Reports, 2013, v. 8, n. 1, p. 22, doi. 10.1007/s11899-012-0142-1
- By:
- Publication type:
- Article
The combination of ibrutinib and rituximab demonstrates activity in first‐line follicular lymphoma.
- Published in:
- British Journal of Haematology, 2020, v. 189, n. 4, p. 650, doi. 10.1111/bjh.16424
- By:
- Publication type:
- Article
Tumour debulking and reduction in predicted risk of tumour lysis syndrome with single‐agent ibrutinib in patients with chronic lymphocytic leukaemia.
- Published in:
- British Journal of Haematology, 2019, v. 186, n. 1, p. 184, doi. 10.1111/bjh.15791
- By:
- Publication type:
- Article
Bendamustine, bortezomib and rituximab produces durable complete remissions in patients with previously untreated, low grade lymphoma.
- Published in:
- British Journal of Haematology, 2018, v. 180, n. 3, p. 365, doi. 10.1111/bjh.15044
- By:
- Publication type:
- Article
Use of anticoagulants and antiplatelet in patients with chronic lymphocytic leukaemia treated with single-agent ibrutinib.
- Published in:
- British Journal of Haematology, 2017, v. 178, n. 2, p. 286, doi. 10.1111/bjh.14660
- By:
- Publication type:
- Article
Phase II study of bendamustine, bortezomib and dexamethasone ( BBD) in the first-line treatment of patients with multiple myeloma who are not candidates for high dose chemotherapy.
- Published in:
- British Journal of Haematology, 2017, v. 177, n. 2, p. 254, doi. 10.1111/bjh.14536
- By:
- Publication type:
- Article
Real-world clinical experience in the Connect<sup>®</sup> chronic lymphocytic leukaemia registry: a prospective cohort study of 1494 patients across 199 US centres.
- Published in:
- British Journal of Haematology, 2016, v. 175, n. 5, p. 892, doi. 10.1111/bjh.14332
- By:
- Publication type:
- Article
Otlertuzumab ( TRU-016), an anti- CD37 monospecific ADAPTIR<sup>™</sup> therapeutic protein, for relapsed or refractory NHL patients.
- Published in:
- British Journal of Haematology, 2015, v. 168, n. 1, p. 38, doi. 10.1111/bjh.13099
- By:
- Publication type:
- Article
A randomized, open-label, multicentre, phase 2/3 study to evaluate the safety and efficacy of lumiliximab in combination with fludarabine, cyclophosphamide and rituximab versus fludarabine, cyclophosphamide and rituximab alone in subjects with relapsed chronic lymphocytic leukaemia
- Published in:
- British Journal of Haematology, 2014, v. 167, n. 4, p. 466, doi. 10.1111/bjh.13061
- By:
- Publication type:
- Article
Open-label, single-arm, phase II study of enzastaurin in patients with follicular lymphoma.
- Published in:
- British Journal of Haematology, 2014, v. 166, n. 1, p. 91, doi. 10.1111/bjh.12853
- By:
- Publication type:
- Article
Ponatinib in patients with refractory acute myeloid leukaemia: findings from a phase 1 study.
- Published in:
- British Journal of Haematology, 2013, v. 162, n. 4, p. 548, doi. 10.1111/bjh.12382
- By:
- Publication type:
- Article
Brief-Duration Rituximab/Chemotherapy Followed by Maintenance Rituximab in Patients With Diffuse Large B-Cell Lymphoma Who Are Poor Candidates for R-CHOP Chemotherapy: A Phase II Trial of the Sarah Cannon Oncology Research Consortium.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2010, v. 10, n. 1, p. 44, doi. 10.3816/CLML.2010.n.004
- By:
- Publication type:
- Article
Prognostic information and biological insights in chronic lymphocytic leukemia by high-resolution immunophenotypic analysis of ZAP70.
- Published in:
- Cytometry. Part A, 2014, v. 85, n. 9, p. 798, doi. 10.1002/cyto.a.22485
- By:
- Publication type:
- Article
Is There Still a Role for PI3K Inhibitors in CLL?
- Published in:
- Clinical Advances in Hematology & Oncology, 2023, v. 21, n. 4, p. 192
- By:
- Publication type:
- Article
Highlights in Mantle Cell Lymphoma From the 62nd American Society of Hematology Annual Meeting and Exposition: Commentary.
- Published in:
- Clinical Advances in Hematology & Oncology, 2021, v. 19, p. 17
- By:
- Publication type:
- Article
The impact of early versus late tocilizumab administration in patients with cytokine release syndrome secondary to immune effector cell therapy.
- Published in:
- Journal of Oncology Pharmacy Practice, 2023, v. 29, n. 1, p. 45, doi. 10.1177/10781552211052635
- By:
- Publication type:
- Article